The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

References

• US National Library of Medicine. Multiple Sclerosis (MS). http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed August 14, 2014
   Google Scholar
• National Multiple Sclerosis Society. Types of MS. http://www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed August 14, 2014
   Google Scholar
• Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 2013;19:S15-S20
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ghushchyan V, Brett McQueen R, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord 2014;3:227-36
   PubMed Web of Science ®Google Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363-79
   PubMed Web of Science ®Google Scholar
• Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 2013;16:639-47
   PubMedGoogle Scholar
• Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522; discussion 22
   PubMed Web of Science ®Google Scholar
• Oleen-Burkey M, Cyhaniuk A, Swallow E. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. J Med Econ 2013;16:397-406
   PubMedGoogle Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Social Security Administration. Actuarial life table: Period life table, 2013. http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed March 29, 2014
   Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
   PubMedGoogle Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand 1982;65:248-66
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27
   PubMed Web of Science ®Google Scholar
• Tolley K, Hutchinson M, You X, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One 2015;10:e0127960
   PubMed Web of Science ®Google Scholar
• Biogen, Weston, MA. Mixed treatment comparison. Data on file; 2014
   Google Scholar
• Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;17:970-9
   PubMed Web of Science ®Google Scholar
• RED BOOK® ; 2016. Truven Health Analytics, Inc. http://www.micromedexsolutions.com/home/. Accessed February 3, 2016
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician Fee Schedule; 2014. http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed April 4, 2014
   Google Scholar
• Centers for Medicare & Medicaid Services. Lab Fee Schedule; 2014. http://www.cms.gov/apps/ama/license.asp?file=/ClinicalLabFeeSched/downloads/14CLAB.zip. Accessed April 4, 2014
   Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• US Department of Labor: Bureau of Labor Statistics. Consumer Price Index—All Urban Consumers. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed March 29, 2014
   Google Scholar
• Bonafede MM, Johnson BH, Wenten M, et al. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Clin Ther 2013;35:1501-12
   PubMed Web of Science ®Google Scholar
• O’Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
   PubMedGoogle Scholar
• Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-beta1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015;29:71-81
   PubMed Web of Science ®Google Scholar
• Tysabri® (natalizumab) [package insert]. Cambridge, MA: Biogen, Inc.; 2016
   Google Scholar
• Gilenya® (fingolimod) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016
   Google Scholar
• Tecfidera® (dimethyl fumarate) [package insert]. Cambridge, MA: Biogen, Inc.; 2016
   Google Scholar
• Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy 2009;7:91-108
   PubMedGoogle Scholar
• Dee A, Hutchinson M, De La Harpe D. A budget impact analysis of natalizumab use in Ireland. Ir J Med Sci 2012;181:199-204
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• Rebif® (interferon beta-1a) [package insert]. Rockland, MA: EMD Serono, Inc.; 2015
   Google Scholar
• Copaxone® (glatiramer acetate) [package insert]. Overland Park, KS: Teva Neuroscience, Inc.; 2016
   Google Scholar
• Plegridy® (peginterferon beta-1a) [package insert]. Cambridge, MA: Biogen, Inc.; 2016
   Google Scholar
• Aubagio® (teriflunomide) [package insert]. Cambridge, MA: Genzyme Corporation; 2016
   Google Scholar
• Lemtrada^® (alemtuzumab) [package insert]. Cambridge, MA: Genzyme Corporation; 2016
   Google Scholar